A. They cause generalized immune suppression. B. They have limited therapeutic potential due to systemic side effects. C. They may be used to treat patients with early-onset multiple sclerosis. D. They are meant to be used in combination with other agents.

A. Natalizumab should only be used as monotherapy. B. Natalizumab should only be used by patients who have not responded to first-line disease modifying therapies. C. Magnetic resonance imaging should be performed prior to initiating therapy with natalizumab in patients with multiple sclerosis. D. Patients with tachycardia are excluded from natalizumab therapy.

A. Adherence B. Patient Cost shares C. Depression D. Lifetime caps on insurance coverage

A. Glatiramer acetate B. Natalizumab C. IFN?-1a D. IFN?-1b